Latest Financials News

PYC Therapeutics has launched a A$653 million capital raising to fund the clinical advancement of four RNA-based drug candidates targeting genetic diseases with significant unmet needs. The raise extends the company’s cash runway to 2030, supporting key clinical milestones and a transition to commercialisation.

PYC Therapeutics has launched a substantial $653 million equity raise to fund clinical trials for four promising drug candidates targeting genetic diseases. This capital injection aims to advance the company’s pipeline through critical human efficacy milestones.

Cyclopharm has reported a record $32.3 million in operating revenue for FY2025, led by explosive growth in its U.S. Technegas market following FDA approval. The company reaffirms its ambitious target of 250–300 U.S. installations by mid-2026 amid strong clinical momentum.

Kairos Minerals has been granted a 21-year mining lease for its 1.4 million ounce Mt York Gold Project in Western Australia, marking a pivotal step towards advancing the project into production.

EV Resources has launched its first-ever diamond drilling program at the Los Lirios Antimony Project in Mexico, aiming to unlock the potential of a historically high-grade mineral system. The company is also refining assay methods to ensure accurate measurement of antimony content.

The ASX has suspended trading in Aspermont Limited, Koba Resources, and WA Kaolin due to their failure to lodge required periodic reports on time. The suspension may be lifted if the companies submit their reports promptly.

Corporate Travel Management's founder Jamie Pherous retires, handing over leadership to Ana Pedersen as the company navigates accounting challenges and aims to relist on the ASX.

FortifAI Limited has completed its acquisition of FastAI Pty Ltd, gaining control of the innovative Nol8 technology and appointing seasoned executive Yosef Keret as director and Celerriem CEO.

F.F.I. Holdings anticipates a modest decline in half-year profit, citing one-off lease expenses despite steady food operations.

CurveBeam AI has received the first A$4 million tranche of a planned A$10 million strategic investment from a leading Chinese orthopaedic device company, marking a significant step in its expansion into the Chinese market.

Genetic Signatures has appointed Maria Halasz as its new CEO, bringing over two decades of leadership in life sciences and capital markets to steer the company’s global expansion.

The Mozambique Government’s approval to restart the TotalEnergies-led LNG project has accelerated construction and workforce mobilisation, positioning RBR Group to capitalise on significant near-term opportunities.